×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCGN – ocugen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/25
02:37 pm
ocgn
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
Low
Report
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
3/25
08:03 am
ocgn
Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.
3/24
05:57 pm
ocgn
Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]
Low
Report
Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]
3/24
05:56 pm
ocgn
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]
Low
Report
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]
3/24
03:21 pm
ocgn
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]
Neutral
Report
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]
3/24
07:45 am
ocgn
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
3/24
02:35 am
ocgn
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge [Yahoo! Finance]
3/23
12:46 pm
ocgn
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks [Yahoo! Finance]
Low
Report
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/24
12:02 pm
ocgn
Form 8-K Ocugen, Inc. For: Mar 24
Medium
Report
Form 8-K Ocugen, Inc. For: Mar 24
3/20
08:00 am
ocgn
Form 8-K Ocugen, Inc. For: Mar 12
High
Report
Form 8-K Ocugen, Inc. For: Mar 12
3/5
09:27 am
ocgn
Form 3 Ocugen, Inc. For: Mar 04 Filed by: Johnson-Greene Treerita Essalima
Medium
Report
Form 3 Ocugen, Inc. For: Mar 04 Filed by: Johnson-Greene Treerita Essalima
3/4
11:38 am
ocgn
Form 10-K Ocugen, Inc. For: Dec 31
Low
Report
Form 10-K Ocugen, Inc. For: Dec 31
3/4
11:12 am
ocgn
Form 8-K Ocugen, Inc. For: Mar 04
Low
Report
Form 8-K Ocugen, Inc. For: Mar 04
3/4
11:08 am
ocgn
Form 8-K Ocugen, Inc. For: Mar 04
Low
Report
Form 8-K Ocugen, Inc. For: Mar 04
2/9
07:59 am
ocgn
Form 8-K Ocugen, Inc. For: Feb 09
Low
Report
Form 8-K Ocugen, Inc. For: Feb 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/9
Ocugen Announces Share Repurchase Program
32.3%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
TOP News Decliners
9/30
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
-59.3%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: